No Data
No Data
No Data
No Data
No Data
Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements
TipRanksApr 26 02:07 ET
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Matterport, Inc. (NASDAQ:MTTR) rose sharply during Monday's session.CoStar Group, Inc. (NASDAQ:CSGP) anno
BenzingaApr 22 10:10 ET
Express News | Lexeo Therapeutics Announces In-License Agreement With Cornell University To Expedite Development Of LX2006 For Treatment Of Friedreich Ataxia Cardiomyopathy; Under Agreement, Co. Has Acquired Certain Rights1 Including Rights To Current And Future Data Ge
Moomoo 24/7Apr 22 07:32 ET
Express News | Lexeo Therapeutics: In-License Agreement With Cornell University
Moomoo 24/7Apr 22 07:31 ET
Express News | Lexeo Therapeutics Inc: Interim Readout of Combined Data Set at Multiple Doses Expected Mid-Year 2024
Moomoo 24/7Apr 22 07:30 ET
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.
GlobeNewswireApr 22 07:30 ET
No Data
No Data